SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bonfim C)
 

Sökning: WFRF:(Bonfim C) > Hematopoietic cell ...

Hematopoietic cell transplantation for telomere biology diseases: A retrospective single-center cohort study

Nichele, S. (författare)
Bonfim, C. (författare)
Luiz, G. D. (författare)
visa fler...
Loth, G. (författare)
Kuwahara, C. (författare)
Trennephol, J. (författare)
Funke, V. A. M. (författare)
Marinho, D. E. (författare)
Koliski, A. (författare)
Rodrigues, A. M. (författare)
Mousquer, R. T. G. (författare)
Fasth, Anders, 1945 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics
Lima, A. C. M. (författare)
Calado, R. T. (författare)
Pasquini, R. (författare)
visa färre...
 (creator_code:org_t)
2023
2023
Engelska.
Ingår i: European Journal of Haematology. - 0902-4441. ; 111:3, s. 423-31
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Telomere biology diseases (TBD) result from defective telomere maintenance, leading to bone marrow failure. The only curative treatment for aplastic anemia related to TBD is a hematopoietic cell transplant (HCT). Although reduced-intensity conditioning (RIC) regimens decrease transplant-related mortality, non-hematological phenotypes represent a major challenge and are associated with poor long-term follow-up outcomes.Objective: To describe the outcome of TBD patients transplanted for marrow failure.Study Design: This is a retrospective, single-center study describing the outcomes of 32 consecutive transplants on 29 patients between 1993 and 2019.Results: The median age at transplantation was 14 years (range, 3-30 years). Most patients received a RIC regimen (n = 28) and bone marrow (BM) from an unrelated donor (n = 16). Four patients received a haploidentical transplant. Chimerism was available for 27 patients with a median time to neutrophil recovery of 20 days (13-36 days). Primary graft failure occurred in one patient, whereas second graft failure occurred in two. Acute GVHD grade II-IV and moderate to severe chronic GVHD occurred in 22% of patients at risk. Fourteen patients were alive after HCT at the last follow-up (median, 6 years; 1.4-19 years). The 5-year overall survival was better after matched sibling donor (MSD) transplantation compared to other hematopoietic stem cell sources (88.9% vs. 47.7%; p = .05; CI = 95%). Overall, 15 patients died after HCT, most of them (n = 11) after the first year of transplant, due to non-hematological disease progression or complication of chronic GVHD.Conclusions: Hematopoietic cell transplantation is a potentially curative treatment option for TBD, nonetheless the poor outcome reflects the progression of non-hematologic disease manifestations, which should be considered when transplantation is indicated.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

dyskeratosis congenita
hematopoietic cell transplant
telomere biology
disease
telomeres
bone-marrow-transplantation
versus-host-disease
dyskeratosis-congenita
mixed chimerism
failure
length
cyclophosphamide
complications
mutations
regimen
Hematology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy